Drew Senyei
Drew is a managing director at Enterprise Partners where he leads the life science practice. Drew focuses on investments in pharmaceuticals, biopharmaceuticals, diagnostics, medical devices and consumer healthcare. Drew has served on over 25 public and private boards including Adeza Biomedical, NuVasive, Corixa Corp., Ligand Pharmaceuticals, Nanogen, Inc., and Discovery Partners. He currently sits on the boards of Enterprise portfolio companies including: Anaborex, Ascenta Therapeutics, Celladon, Celula, Complete Genomics, Genoptix, Ophthonix, TargeGen and Xifin.